by Rod Raynovich | Mar 4, 2010 | BIOgraph
Despite a bunch of way-too-late analyst downgrades (JPMorgan, Roth, Hapoalim) MDVN stock is up 1%+ at $13.25 on volume of 8.8M shares. But there are two interesting articles coming out of the Medivation drama: Robert Langreth writing in Forbes offers the potential of...
by Rod Raynovich | Mar 3, 2010 | BIOgraph
Medivation (MDVN) released disappointing Phase III results for its Alzheimer drug, known as dimebon, saying that the drug was ineffective in treating cognitive decline or behavioral disorders. The stock plunged 67% to 13 as of midday trading on Wednesday. In a joint...
